相关实验视频

Updated: Jun 26, 2026

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
10:16

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

7.3K

PAI-1 与索尔提林相关受体-1 的相互作用是肺纤维化所需的

Thomas H Sisson, John J Osterholzer, Lisa Leung

    bioRxiv : the preprint server for biology
    |August 30, 2024
    PubMed
    概括

    血原激活剂抑制剂-1 (PAI-1) 驱动肺纤维化独立于维特罗涅克丁. 一种与sortilin相关受体1 (SorlA) 的新型相互作用调解了这一过程,确定了SorlA作为异常性肺纤维化 (IPF) 的潜在治疗标.

    更多相关视频

    A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization02:46

    A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

    Published on: January 20, 2023

    3.5K
    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    261

    相关概念视频

    The JAK-STAT Signaling Pathway01:20

    The JAK-STAT Signaling Pathway

    Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Acute Respiratory Failure-II01:21

    Acute Respiratory Failure-II

    Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
    The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
    Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

    Chronic Obstructive Pulmonary Disease-II: Pathophysiology

    Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
    Chronic Inflammation
    Chronic Obstructive Pulmonary Disease II: Emphysema01:23

    Chronic Obstructive Pulmonary Disease II: Emphysema

    Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.